Stablecoin Development (SDEV) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stablecoin Development (SDEV) has outperformed Veraxa Biotech (VRXA) over the past year, losing 55.9% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($169.7 million vs $143.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDEV | VRXA |
|---|---|---|
| Share price | $2.78 | $1.20 |
| Market cap | $143.87M | $169.69M |
| 1-day change | -14.46% | +11.11% |
| YTD return | -90.14% | -88.75% |
| 1-year return | -55.87% | -88.53% |
| 5-year return | -99.92% | — |
| EPS (TTM) | $-18.07 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.75 | $27.36 |
| 52-week low | $0.78 | $1.04 |
| Distance from 52-week high | -97.21% | -95.61% |
| Average volume | 11.20M | 267.22K |
| Shares outstanding | 51.75M | 141.41M |
| Employees | 2 | — |
| Sector | Financial Services | Healthcare |
| Industry | Asset Management | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDEV has outperformed VRXA by 32.7 percentage points over the past year.
- The two companies sit in different sectors: Stablecoin Development in Financial Services and Veraxa Biotech in Healthcare.
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Financial Services · Asset Management · 2 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Healthcare · Biotechnology
SDEV vs VRXA FAQ
Which is bigger, Stablecoin Development or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $169.69M compared with $143.87M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, SDEV or VRXA?
SDEV returned -55.87% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Stablecoin Development and Veraxa Biotech in the same industry?
No. Stablecoin Development is in the Financial Services sector, while Veraxa Biotech is in Healthcare.